Clinical Trial Update: Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography [EARLY_Phase 1]

View source ↗

Summary

Early-phase (Phase 1) clinical trial evaluating the copper-64 radiotracer 64Cu-DOTA-AE105 for diagnosing aggressive cancers with PET; the study has completed an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Breast Cancer
• Prostate Cancer

Drugs mentioned

• 64Cu-DOTA-AE105 (64Cu-DOTA-AE105 radiotracer)

Snippet

Sponsor: Rigshospitalet, Denmark | Conditions: Breast Cancer, Prostate Cancer | EARLY_Phase 1 | Status: COMPLETED